Supercharged donor cells aim to stop blood cancer relapse after transplant
NCT ID NCT05473910
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 5 times
Summary
This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia will receive these cells alongside their transplant. The main goals are to check safety and see if the treatment improves cancer-free survival compared to standard transplant alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center
RECRUITINGDallas, Texas, 75246, United States
Contact
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
-
Columbia University
RECRUITINGNew York, New York, 10027, United States
Contact
-
Dana-Farber Cancer Institute - Hematology/Oncology
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Froedert and Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact
Contact
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Mass General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
Memorial Cancer Institute
RECRUITINGHollywood, Florida, 33021, United States
Contact
-
Moffitt Cancer Institute
RECRUITINGTampa, Florida, 33612, United States
Contact
-
Mount Sinai
RECRUITINGNew York, New York, 10029-6696, United States
Contact
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
-
SCRI - Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact
-
SCRI - TriStar Bone Marrow Transplant
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
St. David's South Austin Medical Center
RECRUITINGAustin, Texas, 76704, United States
Contact
-
University North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
-
University of Colorado - Anschutz Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
-
Yale
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Can pressurized oxygen boost cord blood transplants?
- Drug combo aims to break anemia cycle in MDS patients
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Personalized leukemia vaccine aims to outsmart relapse